Literature DB >> 22192593

Block of cloned Kv4.3 potassium channels by dapoxetine.

Imju Jeong1, Sae Woong Kim, Shin Hee Yoon, Sang June Hahn.   

Abstract

Dapoxetine, a short-acting selective serotonin reuptake inhibitor, is widely prescribed for the treatment of patients with premature ejaculation. The effects of dapoxetine were examined on cloned Kv4.3 channels stably expressed in Chinese hamster ovary cells using the whole-cell patch-clamp technique. Dapoxetine not only reduced the peak amplitude of Kv4.3 currents but also accelerated the decay rate of current inactivation in a concentration-dependent manner. Thus, the concentration-dependent reduction in Kv4.3 was measured from the integral of the current during the depolarizing pulse. Dapoxetine decreased the integral of the Kv4.3 currents over the duration of a depolarizing pulse with an IC(50) of 5.3 μM. Analysis of the time dependence of the block gave estimates of an association rate constant (k(+1)) of 3.9 μM(-1)s(-1) and a dissociation rate constant (k(-1)) of 25.6s(-1). The K(D) (k(-1)/k(+1)) was 6.5 μM, similar to the IC(50) value calculated from the concentration-response curve. The block of Kv4.3 by dapoxetine was highly voltage-dependent at a membrane potential coinciding with the activation of the channels. The additional block by dapoxetine displayed a shallow voltage dependence (δ=0.21) in the full activation voltage range. The steady-state inactivation curves were shifted in the hyperpolarizing direction in the presence of dapoxetine. Dapoxetine also caused a substantial acceleration in closed-state inactivation. Dapoxetine produced a significant use-dependent block, which was accompanied by a delayed recovery from inactivation of Kv4.3 currents. These results indicated that dapoxetine potently blocks Kv4.3 currents by both preferentially binding to the open state of the channels and accelerating the closed-state inactivation. These data could provide insight into the mechanism underlying some of the therapeutic actions of this drug.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22192593     DOI: 10.1016/j.neuropharm.2011.12.006

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  7 in total

1.  Effects of dapoxetine on cloned Kv1.5 channels expressed in CHO cells.

Authors:  Imju Jeong; Shin Hee Yoon; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-04-27       Impact factor: 3.000

2.  Auxiliary KChIP4a suppresses A-type K+ current through endoplasmic reticulum (ER) retention and promoting closed-state inactivation of Kv4 channels.

Authors:  Yi-Quan Tang; Ping Liang; Jingheng Zhou; Yanxin Lu; Lei Lei; Xiling Bian; KeWei Wang
Journal:  J Biol Chem       Date:  2013-04-10       Impact factor: 5.157

3.  Paternal dapoxetine administration induced deterioration in reproductive performance, fetal outcome, sexual behavior and biochemistry of male rats.

Authors:  R ElMazoudy; N AbdelHameed; A ElMasry
Journal:  Int J Impot Res       Date:  2015-09-24       Impact factor: 2.896

4.  Dapoxetine: a new option in the medical management of premature ejaculation.

Authors:  Chris G McMahon
Journal:  Ther Adv Urol       Date:  2012-10

5.  Effect of mosapride on Kv4.3 potassium channels expressed in CHO cells.

Authors:  Ki-Wug Sung; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-22       Impact factor: 3.000

6.  Effects of neferine on Kv4.3 channels expressed in HEK293 cells and ex vivo electrophysiology of rabbit hearts.

Authors:  Chen Wang; Yu-fang Chen; Xiao-qing Quan; Huan Wang; Rui Zhang; Jun-hua Xiao; Jia-ling Wang; Cun-tai Zhang; Ji-zhou Xiang; Qiang Tang
Journal:  Acta Pharmacol Sin       Date:  2015-11-23       Impact factor: 6.150

7.  Calcium/calmodulin-dependent protein kinase II associates with the K+ channel isoform Kv4.3 in adult rat optic nerve.

Authors:  Genki Ogata; Gloria J Partida; Anna Fasoli; Andrew T Ishida
Journal:  Front Neuroanat       Date:  2022-09-08       Impact factor: 3.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.